<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Viral meningitis in children: Management, prognosis, and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Viral meningitis in children: Management, prognosis, and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Viral meningitis in children: Management, prognosis, and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cecilia Di Pentima, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management, prognosis, and prevention of viral meningitis in children will be discussed here. The epidemiology, etiology, pathogenesis, clinical manifestations, and diagnosis of viral meningitis in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5980.html" rel="external">
          "Viral meningitis in children: Epidemiology, pathogenesis, and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5983.html" rel="external">
          "Viral meningitis in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H697812472">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H217098065">
         <span class="h2">
          Indications for hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for hospitalization may include [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ill appearance or signs of encephalitis (eg, altered or depressed mental status, focal neurologic abnormalities, seizures) (see
         <a class="medical medical_review" href="/z/d/html/6042.html" rel="external">
          "Acute viral encephalitis in children: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for empiric antimicrobial therapy (see
         <a class="local">
          'Empiric antibiotics'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for intravenous hydration or aggressive pain control (see
         <a class="local">
          'Supportive care'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompromised host
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age younger than one year
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4089245137">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care for children with viral meningitis may include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rest in a quiet, dimly lit room.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          Acetaminophen
         </a>
         and/or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         for headache, pain, and fever;
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         should be avoided because of its association with Reye syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous fluid therapy if poor oral intake and/or prolonged emesis have resulted in hypovolemia. Careful attention to fluid balance is an important aspect of supportive care. The need for fluid repletion must be balanced against the risk of inappropriate secretion of antidiuretic hormone. (See
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Neonates and immunocompromised hosts may require aggressive supportive care for disseminated disease (eg, myocarditis, pericarditis, hepatitis, coagulopathy), particularly with enterovirus (EV), human parechovirus (HPeV), or herpes simplex virus (HSV) infection [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Supportive measures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2136216148">
         <span class="h2">
          Initial empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Viral meningitis may be suspected based upon epidemiologic data, clinical features, and initial cerebrospinal fluid (CSF) studies  (
         <a class="graphic graphic_table graphicRef130017" href="/z/d/graphic/130017.html" rel="external">
          table 1
         </a>
         ), but the clinical features can overlap with bacterial meningitis  (
         <a class="graphic graphic_table graphicRef76324" href="/z/d/graphic/76324.html" rel="external">
          table 2
         </a>
         ) and it can be difficult to exclude bacterial meningitis with certainty based on initial testing. Ultimately, the definitive diagnosis of viral meningitis requires negative bacterial cultures and detection of a viral pathogen in the CSF. (See
         <a class="medical medical_review" href="/z/d/html/5983.html" rel="external">
          "Viral meningitis in children: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         The following sections describe the approach to determining the need for empiric antimicrobial therapy while awaiting bacterial cultures and viral polymerase chain reaction (PCR) studies.
        </p>
        <p class="headingAnchor" id="H1233894635">
         <span class="h3">
          Empiric antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of the initial evaluation can be used to determine the likelihood of bacterial meningitis, which informs the decision of whether to treat with empiric antibiotics pending results of bacterial cultures and PCR studies  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1730576413">
         <span class="h4">
          Assessing risk of bacterial meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical prediction tools can be used in conjunction with clinical judgement to identify patients with a very low risk of bacterial meningitis  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         These tools have more utility for identifying patients with a low risk of bacterial meningitis than they do for identifying patients with bacterial meningitis.
        </p>
        <p>
         Bacterial meningitis prediction rules
         <strong>
          should not be used
         </strong>
         in patients with any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;3 months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ill appearance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune compromise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination findings concerning for meningococcal disease (ie, petechiae or purpura)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSF shunt or recent neurosurgery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pretreatment with antibiotics for another reason (eg, otitis media) within 72 hours prior to lumbar puncture (LP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Traumatic LP
        </p>
        <p>
        </p>
        <p>
         The most well studied and most commonly used prediction rule is the Bacterial Meningitis Score (BMS) [
         <a href="#rid3">
          3,4
         </a>
         ]. The Meningitis Score for Emergencies (MSE) is an alternate tool that can be used in conjunction with the BMS, which may improve the sensitivity, specificity, and negative predictive value (NPV) [
         <a href="#rid5">
          5
         </a>
         ]. However, there are fewer available data on the predictive value of the MSE. In addition, the MSE relies on results of laboratory tests (C-reactive protein [CRP] and procalcitonin), which may not be rapidly available in some settings. If it is not possible to determine the MSE (eg, because serum CRP or procalcitonin levels were not measured or not available), the BMS can be used alone.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Bacterial Meningitis Score (BMS)
         </strong>
         – The BMS includes the following variables [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive CSF Gram stain (2 points)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CSF absolute neutrophil count (ANC) ≥1000 cells/microL (1 point)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CSF protein ≥80 mg/dL (1 point)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral blood ANC ≥10,000 cells/microL (1 point)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of seizure before or at the time of presentation (1 point)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A score of 0 indicates "very low risk" of bacterial meningitis. The BMS has been validated in several studies, most of which used retrospective data, though there has been at least one small prospective study [
         <a href="#rid4">
          4,6
         </a>
         ]. In a meta-analysis of eight validation studies (including 5312 patients), BMS ≥1 predicted bacterial meningitis with sensitivity and specificity of 99.3 and 62.1 percent, respectively [
         <a href="#rid4">
          4
         </a>
         ]. Among the 2283 children classified as "very low risk" (BMS 0), 0.4 percent (nine patients) had bacterial meningitis, yielding an NPV of 99.6 percent. However, in six of the nine misclassified patients, use of the BMS was inappropriate due to either age &lt;3 months or concerning examination findings (ie, petechiae or purpura). Excluding these six patients, the estimated NPV was 99.9 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Meningitis Score for Emergencies (MSE)
         </strong>
         – The MSE includes the following variables [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum procalcitonin &gt;1.20 ng/mL – 3 points
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum CRP &gt;40 mg/L – 1 point
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CSF ANC &gt;1000/mcL – 1 point
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CSF protein &gt;80 mg/dL – 2 points
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A score of 0 indicates very low risk of bacterial meningitis. In a study involving 1009 pediatric patients with CSF pleocytosis, MSE ≥1 predicted bacterial meningitis with a sensitivity of 100 percent, specificity of 83.2 percent, and NPV of 100 percent [
         <a href="#rid5">
          5
         </a>
         ]. In this study, BMS ≥1 had a sensitivity of 96.7 percent, specificity of 51.3 percent, and NPV of 99.4 percent. However, the study included infants as young as 30 days old and, as previously discussed, the BMS is not intended for use in young infants.
        </p>
        <p>
        </p>
        <p>
         Details of interpreting the CSF profile in children who received antibiotics before LP and interpreting traumatic LPs are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">
          "Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Interpretation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1111620864">
         <span class="h4">
          Risk is very low
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children determined to have very low risk of bacterial meningitis (ie, BMS = 0 and without any of the exclusions listed above), supportive care alone is reasonable provided that  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The physical examination is reassuring (including stable vital signs), and
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms have improved following LP or with antipyretic/analgesic therapy and hydration, and
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tick-borne illnesses, including Lyme meningitis, are not a consideration (see
         <a class="medical medical_review" href="/z/d/html/6038.html" rel="external">
          "Lyme disease: Clinical manifestations in children", section on 'Meningitis'
         </a>
         ), and
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adequate follow-up can be assured (within 24 hours in most cases)
        </p>
        <p>
        </p>
        <p>
         If any of these conditions are not met, the decision to treat with empiric antibiotics is individualized based upon the age and clinical status of the child, season, exposure history, findings of the initial evaluation, and adequacy of follow-up care. In view of the serious consequences of delayed treatment for bacterial meningitis, the threshold to initiate empiric antibiotic therapy should be relatively low.
        </p>
        <p>
         It is important to recognize that while the BMS and MSE can help identify patients at very low risk of bacterial meningitis, they do not discriminate between viral meningitis and other types of aseptic meningitis that may require antimicrobial therapy, such as Lyme meningitis. In Lyme-endemic areas during the summer and fall, it can be difficult to distinguish Lyme meningitis from EV meningitis unless the patient had a preceding tick bite and/or erythema migrans. Facial nerve palsy is also strongly suggestive of Lyme disease. (See
         <a class="medical medical_review" href="/z/d/html/6038.html" rel="external">
          "Lyme disease: Clinical manifestations in children", section on 'Meningitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h4">
          Risk is NOT low
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children in whom the risk of bacterial meningitis is
         <strong>
          not
         </strong>
         low (ie, BMS ≥1 or with any of the exclusions listed above) should be hospitalized and treated with empiric antibiotics  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p>
         In select circumstances (eg, an older child or adolescent with normal neurologic examination who received antibiotic therapy prior to the LP and in whom the only feature suggestive of bacterial meningitis is a neutrophil-predominant CSF pleocytosis), it may be reasonable to observe the patient with or without administration of antimicrobials and repeat the LP 24 hours after the initial procedure [
         <a href="#rid2">
          2,7-10
         </a>
         ]. Repeating the LP may help clarify the likely etiology; a shift to mononuclear predominance supports a viral process, while persistent neutrophil predominance supports a bacterial process. However, persistence of neutrophils can also occur with viral meningitis and this should not be used as the only criterion to distinguish between bacterial and viral disease [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h4">
          Empiric regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The empiric antibiotic regimen should cover the most likely bacterial pathogens in the individual host. For pediatric patients beyond the neonatal period, an appropriate empiric regimen includes
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and high doses of a third-generation cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         [if available]). In severely ill or immunocompromised patients, empiric therapy for unusual bacterial pathogens also may be warranted. Additional details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p>
         The addition of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         may be appropriate in endemic areas for tick-borne infections. (See
         <a class="medical medical_review" href="/z/d/html/7912.html" rel="external">
          "Treatment of Rocky Mountain spotted fever"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7907.html" rel="external">
          "Human ehrlichiosis and anaplasmosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Empiric therapy for neonates with suspected bacterial meningitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">
          "Bacterial meningitis in the neonate: Treatment and outcome", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h4">
          Duration of antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who improve symptomatically, empiric antibiotic therapy is usually discontinued when bacterial cultures are negative after 24 to 48 hours and/or an alternative diagnosis is made (eg, by viral PCR) [
         <a href="#rid1">
          1
         </a>
         ]. In patients with persistent symptoms, additional evaluation may be necessary. (See
         <a class="local">
          'Persistent symptoms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1880969625">
         <span class="h3">
          Empiric acyclovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with uncomplicated viral meningitis do
         <strong>
          not
         </strong>
         require empiric antiviral therapy pending results of bacterial cultures and PCR studies. However, empiric treatment with
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         is appropriate in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute encephalitis
         </strong>
         – Empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         therapy is warranted for infants and children presenting with clinical signs of acute encephalitis (eg, CSF pleocytosis accompanied by focal findings on neurologic examination, depressed or altered mental status, seizures, abnormal neuroimaging findings, or abnormal electroencephalography) [
         <a href="#rid1">
          1
         </a>
         ]. Treatment of acute encephalitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5977.html" rel="external">
          "Acute viral encephalitis in children: Treatment and prevention", section on 'Empiric acyclovir'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concern for neonatal HSV infection
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          Acyclovir
         </a>
         therapy is indicated in neonates with suspected HSV infection. Clinical features suggestive of HSV infection in neonates include mucocutaneous vesicles  (
         <a class="graphic graphic_picture graphicRef75059 graphicRef56041 graphicRef78598" href="/z/d/graphic/75059.html" rel="external">
          picture 1A-C
         </a>
         ), seizures, lethargy, respiratory distress, thrombocytopenia, coagulopathy, hypothermia, sepsis-like illness, hepatomegaly, ascites, or elevated transaminases  (
         <a class="graphic graphic_figure graphicRef67814" href="/z/d/graphic/67814.html" rel="external">
          figure 1
         </a>
         ). The role of acyclovir therapy in neonates with CSF pleocytosis who are otherwise well-appearing is less clear. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106744.html" rel="external">
          "The febrile infant (29 to 90 days of age): Management", section on 'Herpes simplex virus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">
          "The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Herpes simplex virus infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunocompromised patients
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          Acyclovir
         </a>
         may be warranted when HSV or varicella-zoster virus are possible etiologies in an immunocompromised patient. (See
         <a class="local">
          'Treatment of specific viral causes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Alternatives to
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         that can be used in the event of an acyclovir shortage are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'If there is an acyclovir shortage'
         </a>
         .)
        </p>
        <p>
         In patients who are clinically improved, empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         may be discontinued when CSF HSV PCR is negative (in neonates, HSV surface cultures and whole-blood or plasma HSV PCR [if obtained] should also be negative) or an alternative diagnosis is made (eg, by EV or multiplex PCR).
        </p>
        <p>
         In patients with persistent symptoms, continuation of empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         and/or additional evaluation may be necessary. (See
         <a class="local">
          'Persistent symptoms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Treatment of specific viral causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the exception of HSV, most cases of confirmed viral meningitis are treated symptomatically and the role of specific antiviral therapy is limited. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EV and HPeV
         </strong>
         – Therapeutic options for serious EV and HPeV infection are limited. This is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HSV
         </strong>
         – HSV meningitis is treated with
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         [
         <a href="#rid1">
          1,12
         </a>
         ]. Dosing is as follows [
         <a href="#rid13">
          13,14
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonatal HSV, 60 mg/kg per day intravenously, divided every eight hours, for a minimum of 21 days (see
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For central nervous system infections in children aged 3 months to 11 years, 30 to 45 mg/kg per day intravenously, divided every eight hours, for a minimum of 14 to 21 days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For central nervous system infections in children ≥12 years old, 30 mg/kg per day intravenously, divided every eight hours, for a minimum of 14 to 21 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatives to
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         that can be used in the event of an acyclovir shortage are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'If there is an acyclovir shortage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arboviruses and lymphocytic choriomeningitis virus
         </strong>
         – Most arboviral and lymphocytic choriomeningitis virus infections of the central nervous system are treated symptomatically. Investigative therapies for West Nile virus are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">
          "Arthropod-borne encephalitides"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1282.html" rel="external">
          "Treatment and prevention of West Nile virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytomegalovirus (CMV)
         </strong>
         – CMV infection in immunocompromised children is treated with
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         . Treatment may also be warranted in immunocompetent children with serious symptomatic CMV infection; however, data are limited. Treatment of CMV in children is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">
          "Overview of cytomegalovirus infections in children", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epstein-Barr virus
         </strong>
         – Epstein-Barr virus infection rarely requires more than supportive therapy. Even in clinical situations where an antiviral treatment would be desirable, it is not clear that the virus responds. This is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Influenza
         </strong>
         – For patients with confirmed or suspected influenza who are hospitalized or who have severe, complicated, or progressive illness, antiviral treatment should be started as soon as possible after symptom onset. Dosing recommendations for the available agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef70571" href="/z/d/graphic/70571.html" rel="external">
          table 3
         </a>
         ). Treatment of influenza infection in children is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
         </strong>
         – Treatment of children with acute SARS-CoV-2 infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">
          "COVID-19: Management in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Varicella-zoster virus
         </strong>
         – Treatment with
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         may improve outcomes, although data are limited in pediatric patients [
         <a href="#rid15">
          15
         </a>
         ]. Treatment of varicella-zoster virus is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8293.html" rel="external">
          "Treatment of herpes zoster", section on 'Neurologic complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Persistent symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         When symptoms persist or worsen in patients with aseptic meningitis, nonviral causes must be considered  (
         <a class="graphic graphic_table graphicRef80651" href="/z/d/graphic/80651.html" rel="external">
          table 4
         </a>
         ). Additional evaluation may include [
         <a href="#rid7">
          7,16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat LP with removal of 3 to 5 mL of CSF, if possible, for additional PCR testing and fungal and mycobacterial cultures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging of the central nervous system and sinuses with magnetic resonance imaging or computed tomography to look for parameningeal infection and acute disseminated encephalomyelitis. (See
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for Lyme disease, ehrlichiosis, and rickettsial infection. (See
         <a class="medical medical_review" href="/z/d/html/7914.html" rel="external">
          "Diagnosis of Lyme disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7907.html" rel="external">
          "Human ehrlichiosis and anaplasmosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">
          "Clinical manifestations and diagnosis of Rocky Mountain spotted fever"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for parasitic infection. (See
         <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">
          "Cysticercosis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">
          "Trichinellosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">
          "Toxoplasmosis: Acute systemic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5729.html" rel="external">
          "Eosinophilic meningitis", section on 'Parasitic etiologies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If infectious etiologies have been excluded, noninfectious causes of aseptic meningitis should be considered, including autoimmune encephalitis, neoplasms, and drug-induced meningitis. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults", section on 'Neoplasms of the leptomeninges'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults", section on 'Drug-induced meningitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with viral meningitis recover completely [
         <a href="#rid17">
          17-19
         </a>
         ]. Some may complain of several weeks of fatigue, irritability, decreased concentration, muscle weakness and spasm, and incoordination after the acute illness [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Prognosis depends upon the age of the child and the etiologic agent. Enteroviral meningitis typically has a benign clinical course, which by definition lacks the neurologic abnormalities that characterize encephalitis or myelitis [
         <a href="#rid20">
          20
         </a>
         ]. The morbidity and mortality are not precisely known, since widespread disease occurs each year and enterovirus (EV) meningitis is not a reportable condition. For particularly susceptible neonatal or immune-compromised hosts, the rates of sequelae and mortality may be as high as 74 and 10 percent, respectively. When death occurs, it is usually due to hepatic failure (with echoviruses) or myocarditis (coxsackieviruses) [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         The duration of symptoms in children is usually less than one week; many report clinical improvement after lumbar puncture (LP) [
         <a href="#rid20">
          20,23
         </a>
         ]. Adolescents and young adults may have a prolonged convalescent stage, with symptoms persisting for several weeks [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Children with EV meningitis generally recover without neurologic sequelae. Several studies have suggested possible long-term neurologic, cognitive, developmental, and language abnormalities in young children following EV meningitis; however, these observations have been inconsistent [
         <a href="#rid18">
          18,25-27
         </a>
         ]. EV71 central nervous system infection with cardiopulmonary involvement has been associated with neurologic sequelae, including delayed development and reduced cognitive function [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Long-term neurologic sequelae have also been reported following human parechovirus (HPeV) meningitis, particularly when infection occurs in early infancy [
         <a href="#rid29">
          29,30
         </a>
         ]. In long-term follow-up studies, developmental delays and other neurologic disabilities have been identified in approximately one-quarter of young infants with HPeV meningitis [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The immune clearance of EV and HPeV is dependent upon an appropriate antibody-mediated response. Individuals with hereditary or acquired defects in B lymphocyte function (eg, agammaglobulinemia, hypogammaglobulinemia, common variable immunodeficiency) may develop persistent, sometimes fatal, chronic meningitis or meningoencephalitis [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Immunocompromised patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hygiene
         </strong>
         – Simple hygienic measures, such as hand washing, particularly after diaper changing, are important to prevent the spread of enteroviruses (EVs). (See
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccines
         </strong>
         – Vaccines are available to prevent poliovirus, influenza, rabies, and some arboviruses (eg, Japanese encephalitis virus, tick-borne encephalitis). An inactivated enterovirus A71 vaccine is licensed in China. Target groups for these vaccines are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2695.html" rel="external">
          "Poliovirus vaccination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">
          "Rabies immune globulin and vaccine"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Vaccines'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Personal protection
         </strong>
         – Personal protection measures to avoid mosquito and tick exposure are a mainstay of prevention. A variety of insect repellants are available. (See
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control
         </strong>
         – When children are hospitalized with aseptic meningitis, contact precautions are indicated for the duration of illness [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15886538">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, 'The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15649.html" rel="external">
          "Patient education: Meningitis in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16955.html" rel="external">
          "Patient education: Viral meningitis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1187.html" rel="external">
          "Patient education: Meningitis in children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for hospitalization
         </strong>
         – Indications for hospitalization may include (see
         <a class="local">
          'Indications for hospitalization'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ill appearance or signs of encephalitis (eg, altered or depressed mental status, focal neurologic abnormalities, seizures)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Need for empiric antimicrobial therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Need for intravenous hydration or aggressive pain control
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompromised host
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &lt;1 year
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Supportive care for children with viral meningitis may include (see
         <a class="local">
          'Supportive care'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rest in a quiet, dimly lit room
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          Acetaminophen
         </a>
         and/or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         for headache, pain, and fever
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravenous fluid therapy if poor oral intake and/or prolonged emesis have resulted in hypovolemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric antibiotic therapy
         </strong>
         – Viral meningitis may be suspected on the basis of epidemiologic data, clinical features, and initial cerebrospinal fluid (CSF) studies  (
         <a class="graphic graphic_table graphicRef130017" href="/z/d/graphic/130017.html" rel="external">
          table 1
         </a>
         ). The results of the initial evaluation can be used to determine the likelihood of bacterial meningitis, which informs the decision to treat with empiric antibiotics pending results of bacterial cultures and polymerase chain reaction (PCR) studies  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Assessing risk of bacterial meningitis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk of bacterial meningitis is very low
         </strong>
         – For most children with suspected viral meningitis who are assessed as having very low risk of bacterial meningitis  (
         <a class="graphic graphic_algorithm graphicRef129845" href="/z/d/graphic/129845.html" rel="external">
          algorithm 1
         </a>
         ), we suggest supportive care alone rather than empiric antibiotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), provided that:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The physical examination is reassuring (including stable vital signs), and
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Symptoms have improved following lumbar puncture (LP) or with antipyretic/analgesic therapy and hydration, and
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tick-borne and Lyme meningitis are not considerations, and
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Adequate follow-up can be assured (within 24 hours in most cases)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If any of these conditions are not met, the decision to treat with empiric antibiotics is individualized based upon the age and clinical status of the child, season, exposure history, findings of the initial evaluation, and adequacy of follow-up care. In view of the serious consequences of delayed treatment for bacterial meningitis, the threshold to initiate empiric antibiotic therapy should be relatively low. (See
         <a class="local">
          'Risk is very low'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk of bacterial meningitis is NOT low
         </strong>
         – Children in whom the risk of bacterial meningitis is not low should be hospitalized and treated with empiric antibiotics, as summarized in the table  (
         <a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">
          table 5
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration of empiric antibiotic therapy
         </strong>
         – For children who improve symptomatically, empiric antibiotic therapy is usually discontinued when bacterial cultures are negative after 24 to 48 hours and/or an alternative diagnosis is made. (See
         <a class="local">
          'Duration of antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric
         </strong>
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         – Most children with viral meningitis do
         <strong>
          not
         </strong>
         require empiric antiviral therapy pending results of PCR testing. However, empiric treatment with acyclovir is appropriate in the following circumstances (see
         <a class="local">
          'Empiric acyclovir'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children presenting with clinical signs of encephalitis (eg, focal neurologic findings, depressed or altered mental status, seizures, abnormal neuroimaging findings, or abnormal electroencephalography) (see
         <a class="medical medical_review" href="/z/d/html/5977.html" rel="external">
          "Acute viral encephalitis in children: Treatment and prevention", section on 'Empiric acyclovir'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neonates with concern for herpes simplex virus (HSV) infection (see
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompromised patients in whom HSV or varicella-zoster virus are possible etiologies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific antiviral therapy
         </strong>
         – With the exception of HSV, most cases of confirmed viral meningitis are treated symptomatically and the role of specific antiviral therapy is limited. Considerations for specific viral etiologies are discussed above. (See
         <a class="local">
          'Treatment of specific viral causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistent symptoms
         </strong>
         – When symptoms persist or worsen, nonviral causes of aseptic meningitis must be considered  (
         <a class="graphic graphic_table graphicRef80651" href="/z/d/graphic/80651.html" rel="external">
          table 4
         </a>
         ). Additional evaluation may be necessary. (See
         <a class="local">
          'Persistent symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Abzug MJ. Viral meningitis and encephalitis. In: Current Pediatric Therapy, 18th, Burg FD, Ingelfinger JR, Polin RA, Gershon AA (Eds), Saunders, Philadelphia 2006. p.810.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer JI, Maur PR, Riley JP, Smith PB. Management of central nervous system infections during an epidemic of enteroviral aseptic meningitis. J Pediatr 1980; 96:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigrovic LE, Kuppermann N, Macias CG, et al. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA 2007; 297:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigrovic LE, Malley R, Kuppermann N. Meta-analysis of bacterial meningitis score validation studies. Arch Dis Child 2012; 97:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mintegi S, García S, Martín MJ, et al. Clinical Prediction Rule for Distinguishing Bacterial From Aseptic Meningitis. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agüero G, Davenport MC, Del Valle Mde L, et al. [Validation of a clinical prediction rule to distinguish bacterial from aseptic meningitis]. Arch Argent Pediatr 2010; 108:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overall JC Jr. Is it bacterial or viral? Laboratory differentiation. Pediatr Rev 1993; 14:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feigin RD, Shackelford PG. Value of repeat lumbar puncture in the differential diagnosis of meningitis. N Engl J Med 1973; 289:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amir J, Harel L, Frydman M, et al. Shift of cerebrospinal polymorphonuclear cell percentage in the early stage of aseptic meningitis. J Pediatr 1991; 119:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilfert CM, Lehrman SN, Katz SL. Enteroviruses and meningitis. Pediatr Infect Dis 1983; 2:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negrini B, Kelleher KJ, Wald ER. Cerebrospinal fluid findings in aseptic versus bacterial meningitis. Pediatrics 2000; 105:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatric Infect Dis Soc 2013; 2:179.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Herpes simplex. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2018. p.437.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaewpoowat Q, Salazar L, Aguilera E, et al. Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes. Infection 2016; 44:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malcom BS, Eiden JJ, Hendley JO. ECHO virus type 9 meningitis simulating tuberculous meningitis. Pediatrics 1980; 65:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logan SA, MacMahon E. Viral meningitis. BMJ 2008; 336:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics 1993; 92:206.
          </a>
         </li>
         <li class="breakAll">
          Bronstein DE, Glaser CA. Aseptic meningitis and viral meningitis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.484.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rotbart HA. Viral meningitis. Semin Neurol 2000; 20:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan MH, Klein SW, McPhee J, Harper RG. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis 1983; 5:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis 1986; 8:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe M, Srugo I, Tirosh E, et al. The ameliorating effect of lumbar puncture in viral meningitis. Am J Dis Child 1989; 143:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawyer MH. Enterovirus infections: diagnosis and treatment. Semin Pediatr Infect Dis 2002; 13:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilfert CM, Thompson RJ Jr, Sunder TR, et al. Longitudinal assessment of children with enteroviral meningitis during the first three months of life. Pediatrics 1981; 67:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sells CJ, Carpenter RL, Ray CG. Sequelae of central-nervous-system enterovirus infections. N Engl J Med 1975; 293:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergman I, Painter MJ, Wald ER, et al. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr 1987; 110:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hinsbergh TMT, Elbers RG, Hans Ket JCF, et al. Neurological and neurodevelopmental outcomes after human parechovirus CNS infection in neonates and young children: a systematic review and meta-analysis. Lancet Child Adolesc Health 2020; 4:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esposito S, Rahamat-Langendoen J, Ascolese B, et al. Pediatric parechovirus infections. J Clin Virol 2014; 60:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987; 9:334.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Enterovirus (nonpoliovirus). In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.331.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6028 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Abzug MJ. Viral meningitis and encephalitis. In: Current Pediatric Therapy, 18th, Burg FD, Ingelfinger JR, Polin RA, Gershon AA (Eds), Saunders, Philadelphia 2006. p.810.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7359259" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Management of central nervous system infections during an epidemic of enteroviral aseptic meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200475" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22764093" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Meta-analysis of bacterial meningitis score validation studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32843440" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical Prediction Rule for Distinguishing Bacterial From Aseptic Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20204238" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : [Validation of a clinical prediction rule to distinguish bacterial from aseptic meningitis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8361925" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Is it bacterial or viral? Laboratory differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4723106" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Value of repeat lumbar puncture in the differential diagnosis of meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1960611" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Shift of cerebrospinal polymorphonuclear cell percentage in the early stage of aseptic meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6310537" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Enteroviruses and meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10654948" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cerebrospinal fluid findings in aseptic versus bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9524821" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Herpes simplex viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619466" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acyclovir Dosing in the Neonatal Period and Beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619466" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acyclovir Dosing in the Neonatal Period and Beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26680781" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7367078" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : ECHO virus type 9 meningitis simulating tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174598" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Viral meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8337018" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8337018" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11051293" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Viral meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6318288" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3541126" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2729212" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The ameliorating effect of lumbar puncture in viral meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12118843" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Enterovirus infections: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7232044" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Longitudinal assessment of children with enteroviral meningitis during the first three months of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1168853" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sequelae of central-nervous-system enterovirus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2437277" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Outcome in children with enteroviral meningitis during the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377160" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Neurodevelopment and cognition in children after enterovirus 71 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32710840" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Neurological and neurodevelopmental outcomes after human parechovirus CNS infection in neonates and young children: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24690382" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pediatric parechovirus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3296100" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Chronic enteroviral meningoencephalitis in agammaglobulinemic patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
